FDA PDUFA goal date for Oxnimbi (aroxybutynin and atomoxetine) oral NDA.
FDA catalyst calendar
Confirmed PDUFA dates, advisory committees and Phase 3 readouts. Every entry links to its primary source.
3 events · Clear filters
February 2027 1
- 28Feb
Apnimed, Inc. — Oxnimbi (AD109)
March 2027 2
- 16Mar
Aquestive Therapeutics, Inc. — Anaphylm (dibutepinephrine) FDA PDUFA goal date for Class 2 resubmission of Anaphylm sublingual film NDA. - 25Mar
Unicycive Therapeutics, Inc. — oxylanthanum carbonate (OLC) FDA PDUFA target action date for oxylanthanum carbonate (OLC) NDA resubmission.